Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: An analysis from the German Hodgkin Study Group

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8003-8011

  Klimm, Beate ^b   Reineke, Thorsten ^b   Haverkamp, Heinz ^b   Behringer, Karolin ^b   Eich, Hans T ^b   Josting, Andreas ^b   Pfistner, Beate ^b   Diehl, Volker ^b   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG FEVER; ESOPHAGUS DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PAIN; PHARYNX DISEASE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; SKIN DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 32944467461     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.205.60     Document Type: Article

References (44)

1. Diehl V, Stein H, Hummel M, et al: Hodgkin's lymphoma: Biology and treatment strategies for primary, refractory, and relapsed disease. ASH Education Program Book 2003; pp 225-247
2. Sieber M, Franklin J, Tesch H, et al: Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Blood 100:341, 2002 (abstr 341)
3. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003
4. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
5. Klimm B, Engert A, Diehl V: First-line treatment of Hodgkin's lymphoma. Curr Hematol Rep 4:15-22, 2005
6. Josting A, Wiedenmann S, Franklin J, et al: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3440-3446, 2003
7. Rueffer U, Josting A, Franklin J, et al: Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: Incidence, treatment, and prognosis. J Clin Oncol 19:2026-2032, 2001
8. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971-980, 2003
9. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94:182-192, 2002
10. Bhatia S, Yasui Y, Robison LL, et al: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 21:4386-4394, 2003
11. Behringer K, Josting A, Schiller P, et al: Solid tumors in patients treated for Hodgkin's disease: A report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15:1079-1085, 2004
12. Zalcberg J, Kerr D, Seymour L, et al: Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number: Tomudex International Study Group. Eur J Cancer 34:1871-1875, 1998
13. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
14. Smith RS, Chen Q, Hudson MM, et al: Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 21:2026-2033, 2003
15. Gobbi PG, Zinzani PL, Broglia C, et al: Comparison of prognostic models in patients with advanced Hodgkin disease: Promising results from integration of the best three systems. Cancer 91:1467-1478, 2001
16. Hasenclever D: The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 13:75-78, 2002 (suppl 1)
17. Liu S, Semenciw R, Waters C, et al: Time trends and sex patterns in Hodgkin's disease incidence in Canada, 1970-1995. Can J Public Health 91:188-192, 2000
18. Miller TP, LeBlanc M, Braziel RM, et al: Was the bimodal age incidence of Hodgkin's lymphoma a result of mistaken diagnoses of non-Hodgkin's lymphoma? Blood 100:3048, 2002 (abstr 3048)
19. Jeffery GM, Colls BM, Robinson BA, et al: A risk factor for relapse in Hodgkin's disease: Female gender? Hematol Oncol 7:345-353, 1989
20. Flavell KJ, Billingham LJ, Biddulph JP, et al: The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Ann Oncol 14:282-290, 2003
21. Duhmke E, Franklin J, Pfreundschuh M, et al: Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905-2914, 2001
22. Sieber M, Tesch H, Pfistner B, et al: Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: Final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 20:476-484, 2002
23. Sieber M, Tesch H, Pfistner B, et al: Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: Final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 15:276-232, 2004
24. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
26. Brosteanu O, Hasenclever D, Loeffler M, et al: Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol 83:176-182, 2004
27. MacLeod SL, Nowell S, Massengill J, et al: Cancer therapy and polymorphisms of cytochromes P450. Clin Chem Lab Med 38:883-887, 2000
28. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004
29. Milano G, Etienne MC, Cassuto-Viguier E, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175, 1992
30. Stein BN, Petrelli NJ, Douglass HO, et al: Age and sex are independent predictors of 5-fluorouracil toxicity: Analysis of a large scale phase III trial. Cancer 75:11-17, 1995
31. Tsalic M, Bar-Sela G, Beny A, et al: Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): A prospective study in colorectal cancer patients. Am J Clin Oncol 26:103-106, 2003
32. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation. Int J Cancer 101:253-258, 2002
33. Rousseau A, Marquet P: Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 16:253-262, 2002
34. Yule SM, Price L, McMahon AD, et al: Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 10:455-460, 2004
35. Ferreri AJ, Guerra E, Regazzi M, et al: Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353-358, 2004
36. Carde P, Koscielny S, Franklin J, et al: Early response to chemotherapy: A surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 13:86-91, 2002 (suppl 1)
37. Hasenclever D: How to minimize overtreatment: Model based design of studies on response adapted therapy (RAT). Eur J Haematol 73:16, 2004 (abstr 16)
38. Zanotti R, Trolese A, Ambrosetti A, et al: Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 13:1908-1914, 2002
39. Rosenwald A: DNA microarrays in lymphoid malignancies. Oncology (Huntingt) 17:1743-1748, 2003
40. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
41. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
42. Engel C, Loeffler M, Schmitz S, et al: Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 11:1105-1114, 2000
43. Diehl V, Brillant C, Franklin J, et al: Beacopp chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood 104:307, 2004 (abstr 307)
44. Wilson WH, Grossbard ML, Pittaluga S, et al: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002